Cerus (CERS) to Release Earnings on Tuesday

Cerus (NASDAQ:CERS - Get Free Report) is anticipated to release its earnings data after the market closes on Tuesday, March 4th. Analysts expect Cerus to post earnings of ($0.01) per share and revenue of $52.95 million for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Cerus (NASDAQ:CERS - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The business had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Up 3.8 %

Shares of NASDAQ:CERS traded up $0.06 during trading hours on Friday, hitting $1.65. The company's stock had a trading volume of 1,434,793 shares, compared to its average volume of 1,475,356. The firm's fifty day moving average price is $1.74 and its 200 day moving average price is $1.82. Cerus has a 52 week low of $1.38 and a 52 week high of $2.59. The company has a market capitalization of $306.43 million, a price-to-earnings ratio of -15.00 and a beta of 1.29. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92.

Remove Ads

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an "overweight" rating and set a $4.00 target price on shares of Cerus in a report on Friday, February 21st.

Insider Activity

In other Cerus news, Director Eric Bjerkholt sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $1.78, for a total value of $35,600.00. Following the completion of the sale, the director now directly owns 162,133 shares in the company, valued at $288,596.74. This trade represents a 10.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.40% of the company's stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.